<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01407770</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00011809</org_study_id>
    <secondary_id>U10CA081851</secondary_id>
    <secondary_id>REBACCCWFU97609</secondary_id>
    <nct_id>NCT01407770</nct_id>
  </id_info>
  <brief_title>Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer</brief_title>
  <official_title>Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x rays to kill tumor cells. Radiation therapy&#xD;
      may cause skin reactions when patients are exposed to high-energy x rays. Studying the&#xD;
      genetic pattern of patients before and after radiation therapy may help doctors prevent&#xD;
      toxicity and plan the best treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial studies genetic susceptibility to radiation-induced skin&#xD;
      reactions in racial/ethnic groups of patients with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To develop and validate prediction biomarkers for radiation therapy (RT)-induced acute&#xD;
           and chronic skin reactions and quality of life in five racial/ethnic groups of breast&#xD;
           cancer patients, Whites*, Black/African Americans, Hispanic/Latinos, Asians/Native&#xD;
           Hawaiians/Pacific Islanders, and American Indians/Alaskan Natives. NOTE: *This stratum&#xD;
           is closed as of April 25, 2012.&#xD;
&#xD;
        -  To develop polygenic models of RT-induced skin reactions with a comprehensive evaluation&#xD;
           of genome-wide nonsynonymous single nucleotide polymorphisms (nsSNPs).&#xD;
&#xD;
        -  To evaluate the levels of DNA damage (Comet assay) and radiosensitivity (Cell Cycle G2&#xD;
           Delay assay) in lymphocytes before and after RT.&#xD;
&#xD;
        -  To test the effect of gene-gene and gene-smoking interactions on RT-induced skin&#xD;
           reactions.&#xD;
&#xD;
        -  To assess race-ethnic differences in RT-induced skin reactions, DNA damage, and&#xD;
           radiosensitivity and to determine if the gene effects are consistent across&#xD;
           race-ethnicity (gene-race/ethnic interactions).&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to race/ethnicity&#xD;
      (Whites* vs Black/African Americans vs Hispanic/Latinos vs Asians/Native Hawaiians/Pacific&#xD;
      Islanders vs American Indians/Alaskan Natives). NOTE: *This stratum is closed as of April 25,&#xD;
      2012.&#xD;
&#xD;
      Patients undergo adjuvant radiotherapy after breast-conserving surgery.&#xD;
&#xD;
      Blood and urine samples are collected at baseline and last day of radiotherapy for&#xD;
      genotyping, DNA damage, cell cycle assays, urine cotinine, inflammatory immune response&#xD;
      biomarkers, and tumor-killing activity by BeadArray System, Comet assay, flow cytometry-based&#xD;
      assay, Cell-Cycle G2 Delay Assay, Oxygen Radical Absorbance Capacity (ORAC) assay, and ELISA.&#xD;
&#xD;
      Patients are assessed for acute toxicity by research staff using the ONS Criteria for&#xD;
      Radiation-Induced Acute Skin Toxicity at baseline, week 3, and at 1 and 2 months after&#xD;
      radiotherapy. Patients are also assessed for chronic toxicity by research staff using the&#xD;
      Chronic skin toxicity questionnaire (RTOG SOMA Criteria for RT- Induced Breast/Chest Wall&#xD;
      Late Skin Toxicity) at 6 and 12 months after completion of radiotherapy. Photographs of the&#xD;
      breast, chest wall, and contralateral breast are also taken at baseline, week 3, last day of&#xD;
      radiotherapy, and at 1, 2, 6, and 12 months after completion of radiotherapy.&#xD;
&#xD;
      Patients complete the Breast Cancer Risk Study Questionnaire, the Functional Assessment of&#xD;
      Cancer Therapy Breast (FACT-B), the Modified Skindex, and the B39 Quality-of-Life (QOL)&#xD;
      Questionnaire at baseline, last day of radiotherapy, and at 1, 2, 6, and 12 months after&#xD;
      radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2011</start_date>
  <completion_date type="Actual">September 1, 2014</completion_date>
  <primary_completion_date type="Actual">September 1, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of RT-induced early adverse skin reaction (EASR)</measure>
    <time_frame>2 months</time_frame>
    <description>The primary endpoint is RT-related skin reactions which for consistency and clarity across the study we will use the term &quot;Early Adverse Skin Reaction&quot; (EASR). Skin reactions will be assessed at 4 time points from the start of radiotherapy through 2 months of the post radiotherapy follow-up period. The Modified ONS Criteria for Radiation-Induced Acute Skin Toxicity will be used for classification of EASRs related to the skin. The primary outcome variable will be the occurrence (or not) of RT-induced EASR defined as a grade 4 or higher toxicity (based on the ONS criteria) during the 2 months of the follow-up period of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by FACT-B</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life will be assessed using the FACT-B, a modification of the Skindex-16, and a modified version of the NSABP B39 Quality of Life metric.</description>
  </secondary_outcome>
  <enrollment type="Actual">1000</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cognitive Ability, General</condition>
  <condition>Fatigue</condition>
  <condition>Pain</condition>
  <condition>Psychosocial Deprivation</condition>
  <condition>Radiation Toxicity</condition>
  <condition>Skin Abnormalities</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enzyme-linked immunosorbent assay</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>assessment of therapy complications</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>breast irradiation</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Genetic</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole breast irradiation</intervention_name>
    <description>Genetic</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Race/ethnicity to include Whites*, Black/African Americans (AA), Hispanic/Latinos,&#xD;
        Asians/Native Hawaiians/Pacific Islanders, and Native American or Alaskan&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Female patients newly diagnosed with breast carcinoma including ductal carcinoma in&#xD;
             situ (DCIS)&#xD;
&#xD;
               -  Stage 0-IIIA disease&#xD;
&#xD;
          -  Status post-lumpectomy, -quadrantectomy, or -mastectomy&#xD;
&#xD;
          -  Plan to receive adjuvant radiation to the whole breast or chest wall and/or regional&#xD;
             lymph nodes&#xD;
&#xD;
          -  No sites that cannot send blood/urine specimens to Wake Forest by overnight (next day)&#xD;
             express shipping&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  *This stratum is closed as of April 25, 2012.&#xD;
&#xD;
          -  No patients who do not understand English and are unable to complete form with&#xD;
             assistance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Total dose &gt; 40 Gy, dose per fraction &gt; 1.8 - 2.0 Gy, use of 2D, 3D-conformal, or&#xD;
             intensity-modulated radiation therapy (IMRT) treatment techniques allowed; a daily&#xD;
             fraction of 2.7 Gy to the whole breast is suggested for hypofractionated regimens&#xD;
&#xD;
          -  Concurrent and sequential boost techniques are allowed for both standard and&#xD;
             hypofractionated regimens&#xD;
&#xD;
          -  Adjuvant hormonal therapy will be allowed prior to, during, and/or after radiotherapy&#xD;
             (RT) at the discretion of a medical oncologist&#xD;
&#xD;
          -  Targeted therapies, such as Herceptin, will be allowed prior to, during, and/or after&#xD;
             RT at the discretion of the medical oncologist&#xD;
&#xD;
          -  No prior radiation to the involved breast or chest wall&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  No patients who underwent breast reconstruction following mastectomy&#xD;
&#xD;
               -  Placement of tissue expanders and implants are not allowed&#xD;
&#xD;
          -  No patients who have undergone MammoSiteÂ® or any other form of brachytherapy as well&#xD;
             as those who will be treated with skin-sparing IMRT&#xD;
&#xD;
          -  Patients may not be concurrently enrolled in a protocol that involves treatment of the&#xD;
             skin, i.e., applying lotions/moisturizers&#xD;
&#xD;
               -  Protocols that do not involve treatment of the skin are allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James J. Urbanic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar A, Bryant D, Baglan K, Strasser J, Baez-Diaz L, Lesser GJ, Shaw EG. Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. J Clin Oncol. 2018 Aug 20;36(24):2473-2482. doi: 10.1200/JCO.2017.77.1790. Epub 2018 Jul 10.</citation>
    <PMID>29989859</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2011</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>skin reactions secondary to radiation therapy</keyword>
  <keyword>pain</keyword>
  <keyword>fatigue</keyword>
  <keyword>psychosocial effects of cancer and its treatment</keyword>
  <keyword>depression</keyword>
  <keyword>cognitive/functional effects</keyword>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Skin Abnormalities</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

